Document KzezVG30adgLLXV0J0xY26B42

mmi ms* | m j: m Cosmetic, Toiletry and Fragrance Association, Inc. 1133 15IH STREET, N.W.. WASHINGTON, D.C, 2000S- 203/331-1770 TELEX 80-2673 James H. Mori Pitthiertf Mormon F. Eslrln, Ph.D. Vie Prstfdtni--Scitne* . MVnm.{ K -vi TALC SUBCOMMITTEE MINUTES mz'z( s **#&- vfgi X' & rjj 'fy't&flL l*v>r vJ* LS*v'vt;ri :*r?S;.:;*? ;-i a. . ifep ?! kS T : wH'vLmii^e.j,> <., *'.' Nv-tvveJvtrV.H ! ';*x\. 5 !*.-?=_.. -.,' r\; ,: A meeting of the Ta-lc Subcommittee was held on March 31, .1976, at Bristol-Myers, 225 Long. Avenue, Hillside, New Jersey. Those in attendance were: -. George Sandland, Bristol-Myers (CHAIRMAN) John Clements, -Pfizer, Inc. 'Christopher Costello, Colgate-Palmolive .. John Facq, Colgate-Palmolive . Allan Harvey, R.T, Vanderbilt Co., Inc. ;.'Georgs Lee, Johnson 6 Johnson *, 1 .*'' . Ray Kraranes, Whittaker, Clark Daniels -*'Roderick Hundy, Sterling Drug Inc. * ,> Louis Marino;'-'Cyprus Industrial ..Minersls . Fred Roesch, Whittaker, Clark s Daniels . Robert Rolle, Johnson & Johnson Joseph Simko, Colgate-Palmolive-- : . * -, , . Terry Smith, Faberge , , , * . -, .`"Harold Stanley, Charles Pfizer Co. . v ., - ' .'Ian- Stewart, -Walter C. McCrone Assoc., Inc,' > j. , *Robert Suffis, Hennen Co, 5 -'.John Travers, Avon Products, Inc. 'V i..-.Ronald akupcin, Kolmar Labs. Norman Estrin,' CTFA. "' -;.<r.. SaiLdlandAopened, the meeting and proceeded with the agenda. . ?* ::{(i***>**s*:'i ** "*< i,, ,, - i -h 1. Collaborative Study, - -* 'Mr. Lee and Dr. Rolle updated the Subcommittee on reports of: recent gathering- of samples by the Mt. Sinai group. A " ' suggestion was made that individual companies write directly -to Mt. Sinai's, management on the lack of creditability of . ,,Dr. hanger's results when applied to their specific products. I j'j'. -' . ~D e p o n e n t : H; M U ^ V A ^ ' D ate:_ Shirley Q. Casilan, CSR No. 12361 CONFIDENTIAL PLAINTIFF'S EXHIBIT CAM -52 II EXHlBlf K WIT: P E L MO.. 00001785 $ *?:*';>/ ;=;?& -r':4' *? ' %s**-; vr: - 2- The advantages and disadvantages were discussed in detail of engaging in a collaborative study. 'It'was generally felt the Study could not be successful ii' there are restrictions on which talcs can be gathered. Many members favored engaging a collaborative- study'. Dr. Estrin suggested a proposal be put together to be presented to the CTPA Board of Directors (as was done in the case of the microbiological contents study several years ago). A subcommittee was organized to draw up this proposal consisting r, of Mr. Suffis,'Mr. Lee and chaired by Mr. Sandland. 2. Periodic Reporting The Subcommittee agreed on the success o f the presentation of , _ summary reports given to. the PDA.. Dr._ Es.trin suggested the .. Subcommittee should not obligate -itself to give periodic reports to PDA but urged members to build their data base so , that at some time in the future the Subcommittee can decide whether the time is right to present PDA with an update on industry analysis. .. . 3, ' Review of Talc Th planned* review of talc by the Miscellaneous OTG. Drug ..Panel'was noted'. It was suggested CTPA begin at once to plan , for a presentation to be made by a panel of experts, including independent experts, talc suppliers and manufacturers. The '. actual data.for consideration by the ftiscellaenous Panel of summary information on talc was not known. 5. Animal Studies ! -'Dr. Estrin suggested consideration be'given to planning animal .- studies.,,on .talc which may not-be covered adequately by previous, studies. Dr. Travers, Mr.'Roesch and Mr.- Lee will coordinate activities involving Er. Gressal and Dr. Finkalstein to investigate this possibility. 6. Sampling . `The Subcommittee agreed CTFA should not address the issue . raised by Mr. Eiermann and Dr. Schaffo.er further with the FDA. There being no further business, the meeting adjourned. -- i- ;Norman F . .Estrin, Ph.D. Vice president - Science HFE:mp. ;">s CONFIDENTIAL mmem PFI MO 000017S6